Stocks and Investing
Stocks and Investing
Tue, February 16, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Hartaj Singh Maintained (UTHR) at Buy with Increased Target to $275 on, Feb 16th, 2021
Hartaj Singh of Oppenheimer, Maintained "United Therapeutics Corporation" (UTHR) at Buy with Increased Target from $200 to $275 on, Feb 16th, 2021.
Hartaj has made no other calls on UTHR in the last 4 months.
There is 1 other peer that has a rating on UTHR. Out of the 1 peers that are also analyzing UTHR, 0 agree with Hartaj's Rating of Hold.
This is the rating of the analyst that currently disagrees with Hartaj
- Andrew Fein of "HC Wainwright & Co." Upgraded from Hold to Strong Buy and Increased Target to $195 on, Monday, February 1st, 2021
Contributing Sources